India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

The global injectable drug delivery market is experiencing a significant transformation, poised to reach a staggering USD 113 ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

AI, fintech, and other technologies are spurring growth in developing countries, says Lazard Asset Management’s Rohit Chopra.

GLP-1 drugs have been compared to the discovery of penicillin, which changed the course of medicine by treating several ...

Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the ...

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...

Loss per share was $(0.58), falling short of analyst expectations by $(0.13), or 29.1% (GAAP, Q2 2025). - Research and development expenses rose to $60.2 million in Q2 2025, up from $23.8 million in ...

During the pandemic, money flooded into drugmakers’ shares but recently more investors are shifting into Big Tech ...